EMS Pharmaceuticals has announced the start of the sales of the liraglutide, an active ingredient of the medicines Saxenda and Vicloza, who had a decrease in patents
I arrive at the pharmacies next Monday, the first pens for the treatment of obesity AND diabetes 100%national production, announced on Friday 1, the pharmacist EMSProduction manager.
The products have as its prince active the liraglutideSubstance that imitates the action of the LPG-1 hormone, responsible, among other functions, slowing down gastric emptying and increasing insulin production, thus helping to increase satiety and reduce appetite and control blood glucose levels.
So far, the liraglutide has been marketed in the country only through the two reference drugs, Saxenda and Victzaby the Danish pharmacist New Nordisk. National production was possible after the patents of these drugs last year.
According to EMS, two products are launched: the Oilfocused on the control of obesity and with a dosage of 3 mg per day and the LuxSuitable for the treatment of type 2 diabetes and with a dosage of 1.8 mg per day. It is noteworthy that, unlike other GLP-1 analog drugs, such as the traffic lights and the Thypatida, the liraglutide is daily, not weekly.
The new products will have prices suggested by R $ 307.26 (package with 1 pen), $ 507.07 (lux with 2 pens) and $ 760.61 (Olire with 3 penne), according to EMS. Customers who are part of the company discount program will have a 10% lower access to prices.
The pharmacist’s expectation is that national products would be marketed with values lower from 10% to 20% compared to reference medicines, but in the research conducted by Estadão This Friday on pharmacy sites, saxenda and Vicloza are sold with discounts of over 30%, which makes the prices of the two producers very close.
The products will be initially available for the South and the South -est
EMS reported that initially the pens will be available on Raia, Drugsil, Drugs Sao Paulo and Pacheco Drugstore. “The products are already in the distribution centers of these networks and will be available for sale on websites and part of the southern and south -eastern physical stores of the country, with a gradual expansion in other regions in the coming weeks,” said the company.
According to the company, by the end of this year, 250 thousand units of Olire and Lirux should be available in retail.
EMS claims to have invested over $ 1 billion to allow the production of pens in the national territory. For the production of medicines, the company opened the first peptides factory in the country last year.
Located in Hortolândia, inside San Paolo, the plant has the initial ability to produce 20 million pens injectable per year and the possibility of a double production to 40 million.
The company is now preparing to launch the semaglutado (Active ingredient of Ozepic and Wegovy, also from Novo Nordisk) in 2026, after the fall of the patent in the country.
Source: Terra
Rose James is a Gossipify movie and series reviewer known for her in-depth analysis and unique perspective on the latest releases. With a background in film studies, she provides engaging and informative reviews, and keeps readers up to date with industry trends and emerging talents.
